Epalrestat clinical trials
Epalrestat is named as an intervention in 2 current clinical trials in our India and China registers. 1 is recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is St. John's Research Institute (1). The most-studied condition is Diabetic Neuropathy Peripheral.
How Epalrestat works
All drug targets →- Aldose reductase inhibitor InhibitorTarget: AKR1B1 aldo-keto reductase family 1 member BChEMBL only
- Charcot-Marie-Tooth diseasePhase 2
- Breast cancerPhase 2
- Diabetes mellitusPhase 2
- Hepatocellular carcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL56337, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11371, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Epalrestat
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Epalrestat
- ChEMBL
- CHEMBL56337
- DrugBank
- DB15293
- PubChem CID
- 1549120
- CAS number
- 82159-09-9
- FDA UNII
- 424DV0807X
- Wikidata
- Q5382029
- Wikipedia
- Epalrestat
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Epalrestat
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.
NCT06201611 · Diabetic Neuropathy Peripheral
|
Phase 2/3 | Recruiting | St. John's Research Institute | India |
|
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
NCT07557914 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, Diabetes
|
Phase 2 | Not yet open | Haibo Shao | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Epalrestat
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| St. John's Research Institute | 1 |
| Haibo Shao | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in India | 1 | 1 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Epalrestat trials
How many clinical trials are testing Epalrestat?
2 current trials in our India and China registers name Epalrestat as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Epalrestat trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Epalrestat clinical trials?
St. John's Research Institute (1) and Haibo Shao (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Epalrestat works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Epalrestat works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Epalrestat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.